MESO · Mesoblast Limited

Mesoblast’s Q3 FY2026 results mark a critical inflection point in its transition from clinical-stage biotech to commercial cell therapy company. The $30.3 million in Ryoncil® net revenues — derived from gross sales of $35.3 million — represent the strongest quarterly performance since FDA approval in late 2025 and confirm early commercial traction in pediatric SR-aGvHD, with management noting strong February–March demand offsetting January holiday seasonality. Critically, net operating cash outflow narrowed sharply to $4.1 million (versus $34.6 million used in prior quarters), driven by robust customer receipts ($34.6 million) and disciplined cost management across R&D ($13.5M), pre-commercial manufacturing ($9.0M), and marketing ($5.8M). This operational improvement, combined with $75 million drawn from the new $125 million credit facility (entered December 30, 2025), lifted cash to $121.8 million — sufficient for ~41 quarters of current operating burn, per ASX disclosure. The financing structure is strategically significant: the 8% fixed-rate, unsecured-to-secured facility provides long-term flexibility while de-risking near-term liquidity, especially following the $25 million repayment of NovaQuest debt and the pending $4.1 million February 2026 installment. Operationally, the achievement of full patient recruitment in the pivotal CLBP Phase 3 trial and FDA IND clearance for Ryoncil® in Duchenne muscular dystrophy signal meaningful pipeline progression beyond core indications. These developments — alongside the CAR-MSC technology acquisition unveiled at the April R&D Day — reinforce Mesoblast’s positioning as a leader in next-generation allogeneic cell therapies, though commercial scalability and reimbursement execution remain key investor watchpoints.